Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Multidrug-Resistant | 11 | 2024 | 226 | 3.620 |
Why?
|
| Antitubercular Agents | 9 | 2024 | 322 | 2.820 |
Why?
|
| Anti-HIV Agents | 15 | 2021 | 1324 | 1.860 |
Why?
|
| HIV Infections | 26 | 2021 | 5097 | 1.690 |
Why?
|
| Tuberculosis | 9 | 2023 | 543 | 1.630 |
Why?
|
| South Africa | 35 | 2024 | 7596 | 1.290 |
Why?
|
| Adult | 30 | 2024 | 5913 | 1.260 |
Why?
|
| Male | 32 | 2024 | 6754 | 1.240 |
Why?
|
| Retrospective Studies | 17 | 2021 | 799 | 1.190 |
Why?
|
| Female | 33 | 2024 | 9103 | 1.080 |
Why?
|
| Community Health Workers | 2 | 2024 | 66 | 1.060 |
Why?
|
| Humans | 39 | 2024 | 14537 | 1.030 |
Why?
|
| Drug Monitoring | 2 | 2016 | 55 | 0.990 |
Why?
|
| Cost-Benefit Analysis | 4 | 2024 | 253 | 0.940 |
Why?
|
| Linezolid | 1 | 2024 | 22 | 0.930 |
Why?
|
| Diarylquinolines | 1 | 2024 | 39 | 0.920 |
Why?
|
| Motivation | 1 | 2024 | 59 | 0.910 |
Why?
|
| Anti-Retroviral Agents | 4 | 2021 | 551 | 0.890 |
Why?
|
| Rifampin | 4 | 2019 | 197 | 0.880 |
Why?
|
| Focus Groups | 1 | 2024 | 196 | 0.870 |
Why?
|
| Viral Load | 12 | 2019 | 819 | 0.850 |
Why?
|
| Health Care Costs | 6 | 2024 | 115 | 0.840 |
Why?
|
| Primary Health Care | 4 | 2024 | 240 | 0.840 |
Why?
|
| Treatment Failure | 8 | 2018 | 175 | 0.840 |
Why?
|
| Public Sector | 3 | 2018 | 82 | 0.830 |
Why?
|
| Treatment Outcome | 14 | 2021 | 889 | 0.820 |
Why?
|
| Middle Aged | 17 | 2024 | 3601 | 0.790 |
Why?
|
| Patient Compliance | 3 | 2017 | 120 | 0.770 |
Why?
|
| Antibiotics, Antitubercular | 2 | 2018 | 47 | 0.760 |
Why?
|
| Abortion, Spontaneous | 1 | 2021 | 15 | 0.750 |
Why?
|
| Students | 1 | 2021 | 50 | 0.700 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2018 | 472 | 0.700 |
Why?
|
| Premature Birth | 1 | 2021 | 80 | 0.690 |
Why?
|
| Medication Adherence | 3 | 2018 | 151 | 0.650 |
Why?
|
| Proportional Hazards Models | 7 | 2018 | 163 | 0.640 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 280 | 0.600 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2018 | 329 | 0.560 |
Why?
|
| Text Messaging | 1 | 2016 | 25 | 0.540 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2018 | 656 | 0.530 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 529 | 0.530 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2013 | 11 | 0.510 |
Why?
|
| Young Adult | 8 | 2024 | 2498 | 0.500 |
Why?
|
| Drug Resistance, Viral | 2 | 2017 | 278 | 0.490 |
Why?
|
| Counseling | 1 | 2016 | 143 | 0.490 |
Why?
|
| Algorithms | 1 | 2014 | 106 | 0.450 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 56 | 0.450 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 1422 | 0.440 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 151 | 0.440 |
Why?
|
| Cohort Studies | 8 | 2019 | 967 | 0.400 |
Why?
|
| Isoniazid | 2 | 2013 | 110 | 0.400 |
Why?
|
| Adolescent | 7 | 2024 | 2985 | 0.400 |
Why?
|
| Candidiasis, Oral | 1 | 2012 | 8 | 0.400 |
Why?
|
| Malnutrition | 1 | 2012 | 56 | 0.380 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 435 | 0.360 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 279 | 0.350 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 262 | 0.350 |
Why?
|
| Coinfection | 3 | 2021 | 276 | 0.320 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2012 | 324 | 0.310 |
Why?
|
| Lasers, Solid-State | 1 | 2008 | 1 | 0.310 |
Why?
|
| Lasers, Gas | 1 | 2008 | 1 | 0.310 |
Why?
|
| Lasers, Semiconductor | 1 | 2008 | 1 | 0.310 |
Why?
|
| Cell Movement | 1 | 2008 | 13 | 0.310 |
Why?
|
| Fibroblasts | 1 | 2008 | 14 | 0.310 |
Why?
|
| Cell Proliferation | 1 | 2008 | 45 | 0.310 |
Why?
|
| Wound Healing | 1 | 2008 | 29 | 0.300 |
Why?
|
| Qualitative Research | 2 | 2024 | 321 | 0.240 |
Why?
|
| Professional Role | 1 | 2024 | 5 | 0.240 |
Why?
|
| Survival Analysis | 2 | 2017 | 149 | 0.240 |
Why?
|
| Hospitals, Urban | 2 | 2016 | 23 | 0.230 |
Why?
|
| Nitroimidazoles | 1 | 2024 | 24 | 0.230 |
Why?
|
| Child Health Services | 1 | 2024 | 35 | 0.230 |
Why?
|
| Child, Preschool | 3 | 2024 | 1748 | 0.220 |
Why?
|
| HIV-1 | 4 | 2017 | 1260 | 0.220 |
Why?
|
| Government | 1 | 2023 | 13 | 0.220 |
Why?
|
| Prevalence | 5 | 2018 | 1192 | 0.220 |
Why?
|
| Child Development | 1 | 2024 | 93 | 0.220 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 106 | 0.220 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 101 | 0.210 |
Why?
|
| Infant | 3 | 2024 | 2244 | 0.200 |
Why?
|
| Lost to Follow-Up | 2 | 2012 | 62 | 0.190 |
Why?
|
| Logistic Models | 2 | 2013 | 254 | 0.190 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 12 | 0.190 |
Why?
|
| Aged | 4 | 2019 | 1740 | 0.190 |
Why?
|
| Pandemics | 1 | 2023 | 296 | 0.180 |
Why?
|
| Gambia | 1 | 2021 | 13 | 0.180 |
Why?
|
| Mozambique | 1 | 2021 | 55 | 0.180 |
Why?
|
| Referral and Consultation | 2 | 2018 | 57 | 0.180 |
Why?
|
| Tanzania | 1 | 2021 | 88 | 0.180 |
Why?
|
| Universities | 1 | 2021 | 34 | 0.180 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 117 | 0.180 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 38 | 0.180 |
Why?
|
| World Health Organization | 1 | 2021 | 137 | 0.170 |
Why?
|
| Depression | 2 | 2018 | 121 | 0.170 |
Why?
|
| Health Promotion | 1 | 2021 | 109 | 0.170 |
Why?
|
| Data Accuracy | 1 | 2019 | 9 | 0.170 |
Why?
|
| Urban Population | 2 | 2012 | 257 | 0.170 |
Why?
|
| Child, Orphaned | 1 | 2019 | 16 | 0.170 |
Why?
|
| Cost of Illness | 1 | 2021 | 167 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 2 | 2016 | 125 | 0.160 |
Why?
|
| Registries | 1 | 2019 | 91 | 0.160 |
Why?
|
| Politics | 1 | 2019 | 24 | 0.160 |
Why?
|
| Mass Screening | 1 | 2021 | 245 | 0.160 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 17 | 0.160 |
Why?
|
| Health Personnel | 1 | 2021 | 231 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 42 | 0.150 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 135 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2018 | 43 | 0.150 |
Why?
|
| Quality of Life | 1 | 2019 | 177 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 132 | 0.140 |
Why?
|
| Public Health | 1 | 2018 | 124 | 0.140 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 17 | 0.140 |
Why?
|
| Retreatment | 1 | 2016 | 6 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 106 | 0.140 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 33 | 0.140 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 48 | 0.130 |
Why?
|
| Sputum | 1 | 2017 | 135 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2018 | 1160 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2016 | 179 | 0.130 |
Why?
|
| Inpatients | 1 | 2016 | 30 | 0.130 |
Why?
|
| Tenofovir | 1 | 2017 | 171 | 0.130 |
Why?
|
| Benzoxazines | 2 | 2013 | 123 | 0.130 |
Why?
|
| Time Factors | 1 | 2017 | 507 | 0.130 |
Why?
|
| Pregnancy | 1 | 2021 | 1862 | 0.120 |
Why?
|
| Risk Factors | 3 | 2017 | 1475 | 0.120 |
Why?
|
| Phosphorous Acids | 1 | 2013 | 14 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 385 | 0.110 |
Why?
|
| Patient Care | 1 | 2013 | 10 | 0.110 |
Why?
|
| Stavudine | 1 | 2013 | 78 | 0.110 |
Why?
|
| Adenine | 1 | 2013 | 91 | 0.100 |
Why?
|
| Antibodies, Viral | 2 | 2012 | 284 | 0.100 |
Why?
|
| Nevirapine | 1 | 2013 | 146 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 45 | 0.100 |
Why?
|
| Age Factors | 1 | 2013 | 370 | 0.100 |
Why?
|
| Papillomaviridae | 1 | 2011 | 34 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 74 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2012 | 125 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2012 | 321 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 253 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2008 | 2 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Luminescent Measurements | 1 | 2008 | 4 | 0.080 |
Why?
|
| Cell Communication | 1 | 2008 | 3 | 0.080 |
Why?
|
| DNA Damage | 1 | 2008 | 12 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2008 | 79 | 0.080 |
Why?
|
| Cell Survival | 1 | 2008 | 48 | 0.080 |
Why?
|
| Alkaline Phosphatase | 1 | 2008 | 18 | 0.080 |
Why?
|
| Apoptosis | 1 | 2008 | 40 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2008 | 51 | 0.080 |
Why?
|
| Self Report | 2 | 2017 | 114 | 0.070 |
Why?
|
| Hospitalization | 2 | 2021 | 418 | 0.060 |
Why?
|
| Alkynes | 2 | 2013 | 117 | 0.050 |
Why?
|
| Cyclopropanes | 2 | 2013 | 123 | 0.050 |
Why?
|
| Child | 2 | 2019 | 2242 | 0.050 |
Why?
|
| Incidence | 2 | 2013 | 685 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 42 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2021 | 95 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 80 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 21 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 156 | 0.040 |
Why?
|
| Anemia | 1 | 2018 | 41 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 40 | 0.040 |
Why?
|
| Disclosure | 1 | 2017 | 25 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 34 | 0.040 |
Why?
|
| Erythrocyte Indices | 1 | 2016 | 7 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 563 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 74 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 225 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 43 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2017 | 215 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 468 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 480 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 411 | 0.030 |
Why?
|
| Isoxazoles | 1 | 2013 | 4 | 0.030 |
Why?
|
| Oxazolidinones | 1 | 2013 | 4 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2013 | 31 | 0.030 |
Why?
|
| Glucose | 1 | 2013 | 45 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 64 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 33 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 125 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 44 | 0.030 |
Why?
|
| Lamivudine | 1 | 2013 | 89 | 0.030 |
Why?
|
| Anthropometry | 1 | 2013 | 102 | 0.030 |
Why?
|
| Inflammation | 1 | 2013 | 104 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 171 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 105 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2013 | 118 | 0.030 |
Why?
|
| Body Composition | 1 | 2013 | 153 | 0.020 |
Why?
|
| Biomarkers | 1 | 2013 | 327 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 370 | 0.020 |
Why?
|
| Human papillomavirus 11 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Human papillomavirus 6 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Human papillomavirus 18 | 1 | 2011 | 7 | 0.020 |
Why?
|
| Human papillomavirus 16 | 1 | 2011 | 7 | 0.020 |
Why?
|
| Brazil | 1 | 2011 | 47 | 0.020 |
Why?
|
| Botswana | 1 | 2011 | 24 | 0.020 |
Why?
|
| Papillomavirus Vaccines | 1 | 2011 | 18 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2011 | 109 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2012 | 165 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 303 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 2012 | 157 | 0.020 |
Why?
|